| 2.86 -0.01 (-0.35%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.99 |
1-year : | 4.53 |
| Resists | First : | 3.41 |
Second : | 3.88 |
| Pivot price | 3.02 |
|||
| Supports | First : | 2.67 |
Second : | 2.22 |
| MAs | MA(5) : | 2.82 |
MA(20) : | 3.05 |
| MA(100) : | 3.69 | MA(250) : | 3.68 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 26.9 |
D(3) : | 20.9 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 8.35 | Low : | 2.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BFRG ] has closed above bottom band by 28.3%. Bollinger Bands are 60.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.89 - 2.91 | 2.91 - 2.92 |
| Low: | 2.63 - 2.65 | 2.65 - 2.67 |
| Close: | 2.83 - 2.86 | 2.86 - 2.89 |
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Mon, 05 Feb 2024
WallachBeth Capital Announces Closing Of Bullfrog AI $5.7 Million Public Offering - PR Newswire
Thu, 01 Feb 2024
WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering - PR Newswire
Wed, 17 Jan 2024
Dow Tumbles Over 150 Points; Charles Schwab Posts Upbeat Earnings - DatChat (NASDAQ:DATS), Bullfrog AI Hl - Benzinga
Thu, 16 Feb 2023
WallachBeth Capital Announces Closing Of Bullfrog AI Inc. $8.4 Million IPO - PR Newswire
Thu, 16 Feb 2023
Bullfrog AI Announces Closing of $8.4 Million Initial Public Offering - Yahoo Finance
Tue, 14 Feb 2023
WallachBeth Capital Announce Pricing Of Bullfrog AI IPO At $6.50 Per Unit - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 4.13e+006 (%) |
| Held by Institutions | 33.6 (%) |
| Shares Short | 163 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.37e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 257.7 % |
| Return on Equity (ttm) | -234.9 % |
| Qtrly Rev. Growth | 65000 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 692.81 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 187930 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|